Alpha1-Antitrypsin Therapy Suppresses Acute Rejection in an Orthotopic Murine Lung Transplantation Model

α1-antitrypsin (AAT) is an acute phase protein, major inhibitor of neutrophil proteases and considered as a regulatory protein of broad immune and inflammatory responses. Inherited AAT deficiency predisposes to an early-onset pulmonary emphysema and pneumothorax, and is a common indication for lung transplantation. Both preclinical and clinical experience show that therapy with plasma purified AAT is beneficial for emphysema patients with AAT deficiency but also useful for a broad spectrum of inflammatory and immune-mediated diseases.

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: T. Nakagiri, A. Kn öfel, S. Janciauskiene, P. Zardo, S. Wrenger, T. Welte, A. Haverich, G. Warnecke Tags: 363 Source Type: research